Abstract | BACKGROUND: AIM: To assess the efficacy and the tolerability of 8 weeks' oral daily administration of 210 mg of parnaparin sodium compared with placebo in subjects treated with stable-doses of oral aminosalicylates. METHODS: This multicenter, randomized, double-blind proof of concept trial compared the efficacy of CB-01-05 MMX 210 mg tablets to placebo in 141 subjects with mild to moderately active left-sided UC treated with stable-doses of aminosalicylates. The efficacy was assessed by clinical activity index (CAI), endoscopic index (EI) and histological score (HS). RESULTS: A total of 121 subjects (61 in test group and 60 in control group) formed the per protocol (PP) population. After 8 weeks of treatment, clinical remission was achieved in 83.6% of the CB-01-05 MMX group, and in 63.3% in the comparator group (P = 0.011). This effect was also significantly evident in the test group at week 4 (P = 0.028). A significant difference was also detected in rectal bleeding, (disappeared respectively in 75.4% and 55.0%; P = 0.018), and in mucosal friability (recovered respectively in 80.3% and in 56.7%; P = 0.005). CONCLUSIONS: CB-01-05 MMX was safe and significantly effective in treating subjects with mild-to-moderate left-sided UC treated with stable-doses of aminosalicylates.
|
Authors | G Celasco, A Papa, R Jones, L Moro, R Bozzella, M M Surace, G C Naccari, G Gasbarrini |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 31
Issue 3
Pg. 375-86
(Feb 01 2010)
ISSN: 1365-2036 [Electronic] England |
PMID | 19891665
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Anticoagulants
- Delayed-Action Preparations
- Heparin, Low-Molecular-Weight
- parnaparin
|
Topics |
- Administration, Oral
- Adolescent
- Adult
- Aged
- Anticoagulants
(administration & dosage, adverse effects)
- Colitis, Ulcerative
(drug therapy, physiopathology)
- Colon
(drug effects, physiopathology)
- Delayed-Action Preparations
- Dose-Response Relationship, Drug
- Double-Blind Method
- Female
- Heparin, Low-Molecular-Weight
(administration & dosage, adverse effects)
- Humans
- Male
- Middle Aged
- Treatment Outcome
- Young Adult
|